{"product_id":"met-bhn20152487","title":"MET","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eMET\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632527725,"sku":"IR0042002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239646191981,"sku":"IR0042010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239646224749,"sku":"IR0042020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239646257517,"sku":"IR0042050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239646290285,"sku":"IR0042100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239646323053,"sku":"IR0042500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_5f963f4a-5452-4ec1-bc62-683492913990.png?v=1776677729","url":"https:\/\/www.ebiohippo.com\/products\/met-bhn20152487","provider":"BioHippo","version":"1.0","type":"link"}